Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Net Cash Flow (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Net Cash Flow data on record, last reported at $2.8 million in Q2 2025.

  • For Q2 2025, Net Cash Flow fell 47.15% year-over-year to $2.8 million; the TTM value through May 2025 reached -$197000.0, up 98.15%, while the annual FY2025 figure was -$197000.0, 98.15% up from the prior year.
  • Net Cash Flow reached $2.8 million in Q2 2025 per LFCR's latest filing, up from -$4.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $16.1 million in Q2 2023 and bottomed at -$10.4 million in Q3 2023.
  • Average Net Cash Flow over 5 years is $298055.6, with a median of -$179500.0 recorded in 2022.
  • Peak YoY movement for Net Cash Flow: soared 7749.76% in 2023, then plummeted 2628.38% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$1.2 million in 2021, then skyrocketed by 311.86% to $2.6 million in 2022, then plummeted by 307.86% to -$5.4 million in 2023, then skyrocketed by 172.59% to $3.9 million in 2024, then decreased by 27.62% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $2.8 million in Q2 2025, -$4.0 million in Q1 2025, and $3.9 million in Q4 2024.